Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
Rhea-AI Summary
Dermata Therapeutics (NASDAQ: DRMA) opened preorders for Tome Foundational Treatment, its first direct-to-consumer skincare product, ahead of an expected commercial launch and initial shipping date of August 25, 2026. The once-weekly topical mask, positioned as a skin "reset," retails for $178 (about $45 per treatment), with a 10% discount for subscribers.
Each four-treatment kit includes Bioneedle™ powder, an Activator tube, and an application brush, mixed by the user immediately before use. According to Dermata, Tome will be the lead brand for a broader planned portfolio of clinically tested, professional-grade, at-home skincare products.
Positive
- Preorders opened for Tome Foundational Treatment ahead of August 25, 2026 launch
- First direct-to-consumer skincare product under Dermata's Tome brand
- Product pricing disclosed at $178 per four-treatment kit with 10% subscriber discount
Negative
- None.
Market reaction after consumer product launch: DRMA +8.70%
Following this news, DRMA has gained 8.70%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.0% during the session. Our momentum scanner has triggered 6 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.50. Trading volume is exceptionally heavy at 73.2x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 17 | Private placement | Negative | +1.4% | Private placement raised $3.4 million while adding shares and warrants. |
| Aug 11 | Earnings report | Negative | +26.9% | Q2 loss and cash decline accompanied the direct-to-consumer pivot. |
| Aug 05 | Product launch | Positive | +6.4% | Company announced August 25 commercial launch and $178 product pricing. |
| May 13 | Earnings report | Positive | +3.4% | Company advanced the consumer pivot and reported $2.0 million ATM proceeds. |
| Apr 02 | Patent acceptance | Positive | +7.5% | Australian patent application covering topical dermal filler delivery was accepted. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Product, launch, and strategic announcements were followed by positive price reactions, while the recent financing and mixed earnings update also produced positive reactions despite dilution and loss-related concerns.
Key Terms
direct-to-consumer financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Preorders can be made by visiting www.tomeskincare.com -
- Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 -
- Tome Foundational Treatment is a once-weekly topical mask for skin renewal -
SAN DIEGO, CA / ACCESS Newswire / August 21, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is now open to preorders. The Tome Foundational Treatment is expected to start shipping on August 25, 2026.
Beginning today, customers can preorder Tome Foundational Treatment at www.tomeskincare.com. The Foundational Treatment will retail for
"Opening preorders is an exciting milestone for us as we move closer to getting Tome Foundational Treatment into the hands of customers," commented Gerry Proehl, Chief Executive Officer of Dermata. "Over the past year, our team has been focused on preparing for commercialization, including building the Tome brand, researching consumers skincare wants, ordering supplies, designing packaging, optimizing the supply chain, and building a social media presence. With preorders now underway, we are entering the final stage ahead of our planned commercial launch, expected on August 25, 2026," continued Mr. Proehl. "We believe that our Foundational Treatment can fill the "white-space" in the current skincare market by providing consumers with a natural, topical product that is safe to use at home, but provides professional-grade results," concluded Mr. Proehl.
About Tome
Tome is a skincare brand forging a timeless ingredient with modern science to create professional-grade skincare powered by natural and safe ingredients. Built around Bioneedle™, Tome's signature ingredient made from exclusively sourced, wild harvested Spongilla lacustris, a freshwater sponge, Tome's once-weekly Foundational Treatment brings a powerful skin resurfacing treatment into the home. To learn more, visit www.tomeskincare.com
About Dermata
Dermata Therapeutics is a science-driven dermatology company focused on developing innovative skincare solutions that are backed by science and research. Through its consumer brand, Tome, Dermata is expanding its platform to deliver clinically tested skincare products directly to consumers. Dermata is headquartered in San Diego, California. For more information, visit www.dermatarx.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata's shift to commercialize skincare products; the timing of any future announcements; the anticipated benefits of Dermata's strategic shift, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the expected timing and success of any planned product launches; the potential market acceptance of any products; and other factors described in the Company's filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.
Dermata Investors:
Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com
SOURCE: Dermata Therapeutics
View the original press release on ACCESS Newswire